BridgeBio Oncology Therapeutics, Inc. Cash Flow-to-Debt Ratio
BridgeBio Oncology Therapeutics, Inc. cash flow-to-debt ratio. BridgeBio Oncology Therapeutics, Inc. (BBOT) has a Cash Flow-to-Debt Ratio of -0.79x as of March 2026, meaning its operating cash flow of $-35.92 Million could theoretically repay -1% of its total liabilities ($45.37 Million) in one year. Check BBOT operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of BridgeBio Oncology Therapeutics, Inc. (2023–2025)
Cash flow-to-debt ratio of BridgeBio Oncology Therapeutics, Inc. from 2023 to 2025. Historical debt coverage capacity for BridgeBio Oncology Therapeutics, Inc. across 3 annual periods. Also explore BridgeBio Oncology Therapeutics, Inc. annual equity growth to track the company's year-over-year net asset growth rate.
BridgeBio Oncology Therapeutics, Inc. Cash Flow-to-Debt Ratio by Year (2023–2025)
BridgeBio Oncology Therapeutics, Inc. cash flow-to-debt ratio by year from 2023 to 2025. Year-by-year debt coverage analysis for BridgeBio Oncology Therapeutics, Inc.. For the full cash flow conversion analysis, see BridgeBio Oncology Therapeutics, Inc. (BBOT) cash conversion ratio.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -3.05x | $-113.89 Million | $37.28 Million | ▼ -2182.6% |
| 2024 | -0.13x | $-763.82K | $5.71 Million | ▲ +99.9% |
| 2023 | -131.36x | $-52.08 Million | $396.46K | — |